Novo Nordisk Korea said Monday that Ryzodeg, the company’s soluble insulin analog, has increased its share 26.8 percent in the local mixed insulin market within a year of its launch.
The drug is the first insulin combination consisting of 70 percent Tresiba, ultra-long-acting basal insulin, and 30 percent Novorephid, rapid-acting mealtime insulin.
Ryzodeg improved the compliance of patients with diabetes by reducing the number of injections compared with Basal-Bolus therapy, which is a combination of basal insulin and dietary insulin.
According to IMS data, Ryzodeg has recorded steady growth since its launch to rank second in the mixed insulin market with a 26.8 percent share. It marked a nearly a 10-fold increase from 2.6 percent in November 2017 when the drug first launched.
“Ryzodeg's 10-fold growth in the first year of local sales is a valuable result based on the trust of domestic medical staff and patients,” Novo Nordisk Korea CEO Rana Azfar Zafar said. “Based on the efficacy and safety of Ryzodeg, the company aims to become one of the leaders in the mixed insulin market.”
<© Korea Biomedical Review, All rights reserved.>